FDA is once again telling sponsors that the agency is not bound by special protocol assessment (SPA) agreements on the design and size of clinical trial programs. But this time its draft guidance for industry specifies situations in which the agency may revoke an agreement.
Released last week, FDA's Special Protocol Assessment Draft Guidance will replace the final guidance the agency issued in May 2002